Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar frown lines.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Q-Med AB
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Moderate to Very Severe glabellar lines at maximum frown as assessed by the subject and the Investigator and at least Mild glabellar lines at rest

Exclusion Criteria:

• Any previous treatment with any botulinum toxin

• Rhytids of the glabellar region that cannot be smoothed out by manually spreading the skin apart

• Any previous insertion of any permanent or semi-permanent material, hyaluronic acid or collagen fillers to the glabellar region

• Any history of facial surgery above the lower orbital rim

• Any planned facial surgery or aesthetic procedure during the study period

• Ablative skin resurfacing or chemical peels above the lower orbital rim in the previous 12 months or during the study period